Preparation of Hierarchically Porous MBG/CPC Scaffold and Its Performance on Drug Loading and Release

doi:10.3724/SP.J.1077.2013.12301

Abstract

Abstract:

Hierarchically composite scaffold (MBG/CPC) was successfully prepared by loading of mesoporous bioactive glasses (MBG) into macroporous calcium phosphate cement (CPC) with simply centrifuging method. It is revealed that MBG loading capacity on CPC and the BET surface area of MBG/CPC can reach 47.2% and 100.1 m²/g, respectively. In contrast, almost no MBG loading is detected by using traditional impregnation route. Drug loading and releasing tests show that DOX loading capacity on hierarchically composite scaffold MBG/CPC is 46 mg/g, which is 11.5 times of that on pure CPC. Importantly, a sustained drug release in vitro performance is presented on MBG/CPC.

Key words: centrifuging, mesoporous/macroporous, composite scaffold, drug loading, sustained release

CLC Number:

TQ174

DING Feng, LI Nan, LI Yong-Sheng, SHI Jian-Lin. Preparation of Hierarchically Porous MBG/CPC Scaffold and Its Performance on Drug Loading and Release[J]. Journal of Inorganic Materials, 2013, 28(1): 97-102.

Figures/Tables 9

Fig. 1 TEM images of the MBG (a) and SEM images (b) of the MBG

Fig. 2 Small-angle XRD patterns of MBG, CPC, MBG/CPC-I and MBG/CPC-C

Fig.3 Nitrogen adsorption-desorption isotherms and pore size distribution curves (inset) of MBG, CPC, MBG/CPC-I and MBG/CPC-C

Table 1 The pore structure parameters of different samples

Sample	BET surface area/(m²·g^-1)	Pore volume /(cm³·g^-1)	BJH pore size/nm
CPC	9.1	0.05	—
MBG	292.9	0.38	5.4
MBG/CPC-I	14.6	0.05	—
MBG/CPC-C	100.1	0.14	5.4

Fig. 4 UV-Vis absorbance spectra of DOX solutions before and after loading for 24 h with MBG/CPC-C and CPC (a); and digital image of DOX@MBG/CPC-C, DOX@CPC and CPC in day-light (b)

Fig. 5 Calibration curve of the DOX-PBS solutions with different concentrations

Table 2 The DOX loading of different samples

Sample	C₀ /(mg·mL^-1)	C /(mg·mL^-1)	V /mL	m /g	M /(mg·g^-1)
CPC	1.88	1.84	10	0.1	4.0
MBG/CPC-C	1.88	1.42	10	0.1	46.0

Fig. 6 pH dependent DOX release from DOX@CPC (a) and DOX@MBG/CPC-C (b) in PBS buffer

Fig. 7 FT-IR spectra of MBG, CPC and MBG/CPC-C after soaking in SBF for 1 d

References 23

[1]	Wang T W, Wu H C, Wang W R, et al. The development of magnetic degradable DP-bioglass for hyperthermia cancer therapy. J Biomed Mater Res. A, 2007, 83A(3): 828-837.
[2]	Geraci M, Birch J M, Alston R D, et al. Cancer mortality in 13 to 29-year-olds in England and Wales. Br. J. Cancer, 2007, 97(11): 1588-1594.
[3]	Wang J, Chen P, Liu C. The occurrence, inducement and therapy development of bone cancer. World Journal of Traditional Chinese Orthopedics, 2009, 10(2): 120-121.
[4]	Schulman K L, Kohles J. Economic burden of metastatic bone disease in the US. Cancer, 2007, 109(11): 2334-2342.
[5]	Anderson P, Salazar-Abshire M. Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: Physician and nursing perspectives. Curr. Oncol. Rep., 2006, 8(6): 415-422.
[6]	Nagarajan R, Clohisy D R, Neglia J P, et al. Function and quality- of-life of survivors of pelvic and lower extremity osteosarcoma and Ewing's sarcoma: the childhood cancer survivor study,Br. J. Cancer, 2004, 91(11): 1858-1865.
[7]	Meyer J S, Mackenzie W. Malignant bone tumors and limb-salvage surgery in children. Pediatr. Radiol., 2004, 34(8): 606-613.
[8]	Felder-Puig R, Formann A K, Mildner A, et al. Quality of life and psychosocial adjustment of young patients after treatment of bone cancer. Cancer, 1998, 83(1): 69-75.
[9]	Serrano M C, Portoles M T, Pagani R, et al. In vitro positive biocompatibility evaluation of glass-glass ceramic thermoseeds forhyperthermic treatment of bone tumors. Tissue Eng. A, 2008, 14(5): 617-627.
[10]	Hench L L. Bioceramics: from concept to clinic. J. AM. Ceram. Soc., 1991, 74(7): 1487-1510.
[11]	Hench L L. Bioceramics. J. AM. Ceram. Soc., 1998, 81(7): 1705-1728.
[12]	Arcos D, Greenspan D C, Vallet-Regi M. Influence of the stabilization temperature on textural and structural features and ion release in SiO2-CaO-P2O5 Sol-Gel glasses. Chem. Mater., 2002, 14(4): 1515-1522.
[13]	Jokinen M, Rahiala H, Rosenholm J B, et al. Relation between aggregation and heterogeneity of obtained structure in Sol-Gel derived CaO-P2O5-SiO2. J. Sol-Gel. Sci. Technol., 1998, 12(3): 159-167.
[14]	Lindfors N C, Heikkila J T, Aho A J. Long-term evaluation of blood silicon and ostecalcin in operatively treated patients with benign bone tumors using bioactive glass and autogenous bone. J. Biomed. Mater. Res. B, 2008, 87B(1): 73-76.
[15]	Takegami K, Sano T, Wakabayashi H, et al. New ferromagnetic bone cement for local hyperthermia. J. Biomed. Mater. Res., 1998, 43(2): 210-214.
[16]	Yan X X, Yu C Z, Zhou X F, et al. Highly ordered mesoporous bioactive glasses with superior in vitro bone-forming bioactivities. Angew. Chem. Int. Ed., 2004, 43(44): 5980-5984.
[17]	Xia W, Chang J. Well-ordered mesoporous bioactive glasses (MBG): a promising bioactive drug delivery system. J. Control. Release, 2006, 110(3): 522-530.
[18]	Zhao L Z, Yan X X, Zhou X F, et al. Mesoporous bioactive glasses for controlled drug release. Micropor. Mesopor. Mater., 2008, 109(1/2/3): 210-215.
[19]	Lopez-Noriega A, Arcos D, Izquierdo-Barba I, et al. Ordered mesoporous bioactive glasses for bone tissue regeneration. Chem. Mater., 2006, 18(13): 3137-3144.
[20]	Fang L R, Weng W J, Shen G, et al. Research for bone tissue engineering scaffolds and biomaterials. Journal of Biomedical Engineering, 2003, 20(1): 148-152.
[21]	Zhu M, Wang H X, Liu J Y, et al. A mesoporous silica nanoparticulate/b-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy. Biomaterials, 2011, 32(7): 1986-1995.
[22]	Nielsen O S, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. a study of the EORTC soft tissue and bone sarcoma group. Br. J. Cancer, 1998, 78(12): 1634-1639.
[23]	Guo M, Yan Y, Zhang H K, et al. Magnetic and pH-responsive nanocarriers with multilayer core-shell architecture of anticancer drug delivery. J. Mater. Chem., 2008, 18(42): 5104-5112.